key: cord-0896927-9jpuqk4v
authors: Brill, L.; Raposo, C.; Rechtman, A.; Zveik, O.; Levin, N.; Djian, E.; Wolf, D.; Vaknin-Dembinsky, A.
title: SARS-CoV-2 third vaccine immune response in MS patients treated with ocrelizumab
date: 2022-01-28
journal: nan
DOI: 10.1101/2022.01.26.22269876
sha: ce5ed5d5a6381cb19bcb21cac23833b9d135b299
doc_id: 896927
cord_uid: 9jpuqk4v

The introduction of a third dose vaccination along with new variants of concerns raises questions regarding serology and T-cell responses in patients with MS (pwMS) treated with B-cell depletion who develop attenuated humoral response to vaccines. The aim of this study is to longitudinally evaluate humoral and cellular response to SARS-CoV-2 mRNA vaccine in ocrelizumab-treated pwMS before and following third vaccine dose. Following the third vaccine dose, patients who are low or non-responders following initial vaccination did not increase antibody titers. In HCs and ocrelizumab-treated pwMS, cellular response decreased 6 months following initial vaccination and increased significantly after the third booster.

Concerns of waning immunity together with the resurgence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), despite high percent of the population vaccinated with two doses of the mRNA coronavirus disease 2019 (COVID- 19) vaccine, led to the recommendation of a third vaccine dose. Patients with MS (pwMS) treated with B-cell depletion treatments such as ocrelizumab are able to generate a robust T-cell response following two doses of the mRNA vaccine [1] [2] [3] . However, an attenuated humoral response was observed 1, 4, 5 . The cellular response to SARS-CoV-2 is recognizing multiple sites of the receptor-binding domain (RBD) region, thus offering broad reactivity against spike epitopes.

Although SARS-CoV-2 variants of concern (VOC) are able to evade infection or vaccination-induced neutralizing antibodies 6 a robust T cell response described against VOCs, including the newest Omicron variant was recently described 7, 8 . Preservation of vaccine-induced T-cell responses may offer some level of protection to individuals with low antibody response. Whether ocrelizumab will have an impact on the longevity of the anti-SARS-CoV-2 response, and the effect of a third dose on the immune response of patients treated with ocrelizumab, are unknown. We assessed longitudinal humoral and T-cell response in HCs and pwMS treated with ocrelizumab pre and post-third BNT162b2 dose.

This information can help guide treatment and vaccination recommendations.

This single-center study was performed at Hadassah Medical Center, Jerusalem, Israel.

Participants were vaccinated between December 2020 and October 2021 and donated blood for antibody and T-cell assessments 2-8 weeks and 6 months following their second dose and 2-8 weeks following the third vaccine dose (BNT162b2, Pfizer/BioNTech). All participants provided written informed consent (975-20 HMO).

Serology response was measured using spike receptor-binding domain (RBD) Architect SARS-CoV-2 IgG II Quant assay (Abbott Diagnostics). Positive and borderline response defined by IgG titer of ≥50 and 50-100 arbitrary units (AU/ml), respectively.

SARS-CoV-2-specific T-cell response was assessed using T-SPOT ® Discovery SARS-CoV-2 (Oxford Immunotec), using freshly isolated peripheral blood mononuclear cells 1 . Results are presented as the number of IFNγ spot-forming cells (SFCs/250,000 cells). Positive response is defined as SFC≥6. IL-2, IL-4, IL-6, IL-10, TNFα and IL-17 levels were measured in supernatants using BD Cytometric Bead Array Human Inflammatory Cytokines Kit.

Statistical analyses were performed using 1-way ANOVA, student t-test, and Pearson's correlation coefficient. The results are presented as mean (SD). Two-sided P values are statistically significant at less than 0.05. vaccine. The first two doses were given 3 weeks apart, and the third was administered 5-6 months after the second dose. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 28, 2022. ; https://doi.org/10.1101/2022.01.26.22269876 doi: medRxiv preprint 2C-E). The level of IFN-γ secreting cells significantly correlated with IL-2 in both groups (OCR: r=0.3 p=0.035, HC: r=0.5 p<0.001) and with TNFα and IL-6 levels in pwMS treated with ocrelizumab (r=0.35, p=0.002; r=0.39, 0.01, respectively) ( Figure 2F-H) .

The need for a third vaccine dose emerged when an increase in breakthrough cases was observed even after vaccination with two doses of mRNA vaccines. Studies revealed waning vaccine immunity over time 9 and a strong correlation between time of vaccine administration and infection incidence 10, 11 .

Here, we found that SARS-CoV-2-specific T-cell responses decreased 6 months following vaccination and increased significantly after the third dose, both in HCs and pwMS treated with ocrelizumab. Antibody levels also significantly decreased 6 months after the first two doses in both groups, and significantly increased following the third dose in HCs and in a subset of seropositive pwMS treated with ocrelizumab. Data on the effect of a third vaccine dose on people with negative serology is scarce 12 . In organ transplantation it has been reported that 44% of the seronegative patients before the third dose were seropositive afterwards 13 . In a small cohort of rheumatology patients treated with another B-cell-depletion therapy, rituximab, vaccinated seronegative patients remained seronegative after the third vaccine dose with preserved T-cell response 14 . We found that none of the borderline/seronegative patients developed positive serology response post-third dose. All patients with increased antibody levels after the third dose were vaccinated more than five months after the last ocrelizumab infusion, suggesting that it may be possible to optimize the antibody response to vaccination by timing vaccination with regards to the last infusion dose.

pwMS-treated with ocrelizumab providing initial evidence that ocrelizumab may not affect the longevity of the T-cell response. While T-cells have been suggested to have a protective role, in particular in controlling disease severity 15 they also seem to be less influenced from variants that escape antibody neutralization 8 . Omicron, the most recent VOC with a high number of mutations in the receptor binding domain, has been shown to have significant evasion of vaccine-induced neutralizing antibody responses 16, 17 . Most of the experimental Tcell epitopes known to be targeted in vaccinated and/or previously infected are unaffected by Omicron mutations 18 . This highlights the importance of T-cell response following vaccination. Evidence from breakthrough infection will help understand the contribution of All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 28, 2022. ; https://doi.org/10.1101/2022.01.26.22269876 doi: medRxiv preprint antibodies and T-cells in mediating protection from severe COVID-19. A recent study suggested that anti-CD20s-treated patients may be at higher risk of COVID-19 infection 19 .

Nevertheless, the cases were mostly mild, with most patients not requiring hospitalization, none required ICU admission, and none died. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 28, 2022. Data are presented as mean ± SD. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 28, 2022. . All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 28, 2022. ; https://doi.org/10.1101/2022.01.26.22269876 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 28, 2022. ; https://doi.org/10.1101/2022.01.26.22269876 doi: medRxiv preprint

Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nature medicine

Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity. medRxiv

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies. Vaccine

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature

T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals

SARS-CoV-2 vaccination induces immunological memory able to cross-recognize variants from Alpha to Omicron

Waning Immune Humoral Response to BNT162b2 Covid-19

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. The New England journal of medicine

Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine

Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis. Vaccines (Basel)

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. The New England journal of medicine

Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Mapping the antigenic diversification of SARS-CoV

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. bioRxiv

SARS-CoV-2 T Cell Responses Elicited by COVID-19

Vaccines or Infection Are Expected to Remain Robust against Omicron

Clinical features and outcomes of COVID-19

SARS-CoV-2 vaccination in people with multiple sclerosis